Sort
48,018 grants matching “immunotherapy”
Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy
$628,307Dan Landau · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk
$628,294Saikrishna Yendamuri · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Brain Tumors - Immunological and Biological Studies
$628,277Duke University · R37 · FY2004 · CA
Targeting Aldehyde Dehydrogenase for Cancer Prevention
$628,206Gavin P. Robertson · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2021 · CA
Developmental Funds
$628,152Leonidas C Platanias · Northwestern University At Chicago · P30 · FY2018 · CA
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
$628,148Noah M Hahn · Johns Hopkins University · R01 · FY2022 · CA
Immunology of aging and immunotherapy of aging-associated diseases
$628,091Arya Biragyn · National Institute On Aging · ZIA · FY2013 · AG
Cancer Chemotherapy Training Program
$628,051Sloan-Kettering Institute For Cancer Res · T32 · FY2002 · CA
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
$628,036Hongjun Wang · Medical University Of South Carolina · R01 · FY2022 · DK
Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
$627,998David M Holtzman · Washington University · P01 · FY2022 · AG
Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development
$627,973Owen N Witte · University Of California Los Angeles · R01 · FY2019 · CA
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
$627,949Patrick Alexander Ott · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
$627,949Patrick Alexander Ott · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
$627,949Patrick Alexander Ott · Dana-Farber Cancer Inst · R01 · FY2018 · CA
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
$627,949Patrick Alexander Ott · Dana-Farber Cancer Inst · R01 · FY2020 · CA
OVERCOMING LUNG CANCER IMMUNOTHERAPY RESISTANCE BY TARGETING BONE MORPHOGENETIC PROTEINS
$627,906The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2021 · Defense Health Agency
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
$627,894Tomas Kirchhoff · New York University School Of Medicine · R01 · FY2021 · CA
E7 TCR-T cell therapy for HPV-associated cancers
$627,893Christian Hinrichs · Rutgers Biomedical And Health Sciences · U01 · FY2025 · CA
Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism
$627,890Nicholas C Denko · Ohio State University · R01 · FY2023 · CA
Phase 0-1 Clinical Trials
$627,868James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
MRI-Guided Cryoablation and Imaging-Guided Intratumoral Delivery of STING Agonist Immunotherapy to Target Localized and Metastatic Canine Osteosarcoma
$627,858Dara L Kraitchman · Johns Hopkins University · R01 · FY2021 · CA
Multicolor PET to interrogate cancer biology
$627,848Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2024 · EB
Noninvasive imaging and blood biomarkers for personalized lung cancer immunotherapy
$627,705Ruijiang Li · Stanford University · R01 · FY2024 · CA
Defining Intercellular Heterogeneity in Cell Cycle Quiescence
$627,676Jeanette Gowen Cook · Univ Of North Carolina Chapel Hill · R61 · FY2025 · CA
ANTI-PD1 IN COMBINATION WITH AN INHIBITOR OF PCSK9 TO INCREASE MHC CLASS I MOLECULE EXPRESSION ON TUMOR CELLS AS IMMUNOTHERAPY FOR NSCLC
$627,639Duke University · · FY2021 · Defense Health Agency